Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer
Authors
Keywords
-
Journal
ONCOGENE
Volume 41, Issue 2, Pages 191-203
Publisher
Springer Science and Business Media LLC
Online
2021-10-30
DOI
10.1038/s41388-021-02077-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers
- (2020) Dhivya R. Sudhan et al. CANCER CELL
- EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer
- (2020) Vito Amodio et al. Cancer Discovery
- RAS-targeted therapies: is the undruggable drugged?
- (2020) Amanda R. Moore et al. NATURE REVIEWS DRUG DISCOVERY
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
- (2020) David S. Hong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Grb7, a Critical Mediator of EGFR/ErbB Signaling, in Cancer Development and as a Potential Therapeutic Target
- (2019) Pei-Yu Chu et al. Cells
- Biomarker-guided therapy for colorectal cancer: strength in complexity
- (2019) Anita Sveen et al. Nature Reviews Clinical Oncology
- H3K4me2 functions as a repressive epigenetic mark in plants
- (2019) Yuhao Liu et al. Epigenetics & Chromatin
- Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
- (2019) Chune Yu et al. Frontiers in Immunology
- Genome-wide CRISPR-Cas9 screen reveals selective vulnerability of ATRX-mutant cancers to WEE1 inhibition
- (2019) Junbo Liang et al. CANCER RESEARCH
- Tie2–FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in Glioblastoma
- (2019) Xiaolong Li et al. CANCER RESEARCH
- The role of polo‐like kinase 3 in the response of BRAF‐mutant cells to targeted anticancer therapies
- (2019) Mahamat Babagana et al. MOLECULAR CARCINOGENESIS
- Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition
- (2019) Meagan B. Ryan et al. CLINICAL CANCER RESEARCH
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
- (2019) Jill Hallin et al. Cancer Discovery
- Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers
- (2019) Rita Sulahian et al. Cell Reports
- Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
- (2018) Matthew R. Janes et al. CELL
- Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E -Mutant Colorectal Cancer
- (2018) Ryan B. Corcoran et al. Cancer Discovery
- SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models
- (2018) Carmine Fedele et al. Cancer Discovery
- CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response
- (2018) Karol Szlachta et al. Nature Communications
- A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers
- (2018) Tonći Šuštić et al. Genome Medicine
- Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening
- (2017) Julia Joung et al. Nature Protocols
- A combinatorial strategy for treating KRAS-mutant lung cancer
- (2016) Eusebio Manchado et al. NATURE
- Comparing CRISPR and RNAi-based screening technologies
- (2016) Benjamin E Housden et al. NATURE BIOTECHNOLOGY
- Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer
- (2016) H. Kitai et al. Cancer Discovery
- High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities
- (2015) Traver Hart et al. CELL
- Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
- (2015) Ryan B. Corcoran et al. JOURNAL OF CLINICAL ONCOLOGY
- G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab
- (2015) Ondrej Fiala et al. TUMOR BIOLOGY
- Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer
- (2014) S. Misale et al. Science Translational Medicine
- ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer
- (2014) Sandra Van Schaeybroeck et al. Cell Reports
- Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
- (2014) Chong Sun et al. Cell Reports
- RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells
- (2014) Simona Lamba et al. Cell Reports
- MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
- (2013) Paolo A Ascierto et al. LANCET ONCOLOGY
- Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
- (2012) Jeffrey R Infante et al. LANCET ONCOLOGY
- Targeting GRB7/ERK/FOXM1 Signaling Pathway Impairs Aggressiveness of Ovarian Cancer Cells
- (2012) David W. Chan et al. PLoS One
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
- (2012) Ryan B. Corcoran et al. Cancer Discovery
- Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer
- (2011) J. A. Sparano et al. CLINICAL CANCER RESEARCH
- Differential Functions of Growth Factor Receptor-Bound Protein 7 (GRB7) and Its Variant GRB7v in Ovarian Carcinogenesis
- (2010) Y. Wang et al. CLINICAL CANCER RESEARCH
- Dual action of epidermal growth factor: extracellular signal-stimulated nuclear–cytoplasmic export and coordinated translation of selected messenger RNA
- (2010) Nien-Pei Tsai et al. JOURNAL OF CELL BIOLOGY
- A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
- (2009) Ji Luo et al. CELL
- Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer
- (2009) Jens Neumann et al. PATHOLOGY RESEARCH AND PRACTICE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now